A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients with Recurring Uterine Cancer

Trial Title: A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients with Recurring Uterine Cancer

NCT ID: NCT06340568

Condition: Endometrial Cancer

Conditions: Official terms:
Endometrial Neoplasms
Paclitaxel
Doxorubicin

Conditions: Keywords:
Human epidermal growth factor receptor 2 (HER2)
HER2-expressing tumors
Recurrent endometrial cancer
IHC scores 1+, 2+, and 3+
Immune checkpoint inhibitor
Platinum-based therapy
HER2 protein expression
HER2-expressing endometrial cancer
ErbB-2 receptor
Antibody drug conjugate

Study type: Interventional

Study phase: Phase 3

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: BNT323/DB-1303
Description: intravenous (IV) infusion
Arm group label: BNT323/DB-1303

Intervention type: Drug
Intervention name: Doxorubicin
Description: IV bolus or infusion
Arm group label: Doxorubicin or paclitaxel

Intervention type: Drug
Intervention name: Paclitaxel
Description: IV infusion
Arm group label: Doxorubicin or paclitaxel

Summary: The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population.

Detailed description: This is an open-label, randomized, multi-site, Phase III, interventional clinical study designed to determine the efficacy and safety of BNT323/DB-1303 compared with investigator's choice of single agent chemotherapy in previously treated patients with recurrent endometrial cancer, whose disease has progressed on at least one line of platinum-based therapy. Owing to the differences in availability of immune checkpoint inhibitors (ICIs) between countries, there will be two cohorts in the study: - Cohort 1 (main cohort): Patients that have had prior ICI treatment. - Cohort 2 (China only): Patients that have not had prior ICI treatment. In each cohort, patients will be randomized 2:1 to receive either BNT323/DB-1303 or investigator's choice of single agent chemotherapy (doxorubicin or paclitaxel) until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined progressive disease (PD) unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.

Criteria for eligibility:
Criteria:
Key Inclusion Criteria: - Are female adults (defined as ≥18 years of age or acceptable age according to local regulations at the time of voluntarily giving informed consent). - Have histologically confirmed endometrial cancer that: - Is recurrent, - Is documented as HER2 1+, 2+, or 3+ score on immunohistochemistry (IHC) as determined by the Central Laboratory, and - Is not defined as a true sarcoma (i.e., leiomyosarcoma or endometrial stromal sarcoma). Note: Uterine carcinosarcoma is allowed. - Have measurable disease defined by RECIST 1.1. - Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Have a life expectancy of ≥12 weeks at screening. Cohort 1 (main cohort) specific inclusion criteria: - Have had at least one prior line of platinum-based therapy (in any setting) and prior ICI treatment (in any setting). Up to three lines of prior therapy are allowed. Prior hormonal therapy and radiation are allowed and do not count as prior lines of therapy. Platinum-based chemotherapy and ICI may have been given together or in separate lines of therapy. - Note: If a patient discontinues treatment due to treatment-related toxicity (no clear progression) and starts a new anti-cancer treatment, these are counted as one line of therapy. Cohort 2 (China only) specific inclusion criteria: - Have had at least one prior line of platinum-based therapy (in any setting). Up to three lines of prior therapy are allowed. Prior hormonal therapy and radiation are allowed and do not count as prior lines of therapy. Only patients who have not had prior ICI treatment will be enrolled in this cohort. - Note: If a patient discontinues treatment due to treatment related toxicity (no clear progression) and starts a new anti-cancer treatment, these are counted as one line of therapy. Key Exclusion Criteria: - Ineligible for all options in the investigator's choice of chemotherapy arm. Patients with contraindications to paclitaxel and doxorubicin treatment, per local prescribing information and institutional guidelines, cannot be enrolled to the study. - Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to randomization. - Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse events (AEs). - Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization. - Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. - Patients with prior use of immunosuppressive medication within 14 days prior to first dose of study treatment, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses of less than 10 mg/day of prednisone or equivalent, and topical corticosteroids. Patients receiving corticosteroids may continue if the dose is stable upon giving informed consent. - Have a lung-specific intercurrent clinically significant illness including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months prior to study randomization, severe asthma, severe chronic obstructive pulmonary disorder, restrictive lung disease, significant pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy (complete). - Have uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to randomization. - Have unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. - Are pregnant or breastfeeding or are planning pregnancy during the study or within 7 months after last study treatment. - Have a history of allergies, hypersensitivities, or intolerance to the study treatments (investigational medicinal products and auxiliary medicinal product) including any excipients thereof or to other monoclonal antibodies. - Had prior treatment with topoisomerase I inhibitors, including Antibody-drug conjugates (ADCs) with exatecans. - Have left ventricular ejection fraction (LVEF) <50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: November 2024

Completion date: March 2029

Lead sponsor:
Agency: BioNTech SE
Agency class: Industry

Collaborator:
Agency: DualityBio Inc.
Agency class: Industry

Source: BioNTech SE

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06340568